Gentamicin-loaded microspheres for reducing the intracellular Brucella abortus load in infected monocytes

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 6, 2004, Pages 981-988

  Prior, Sandra ^a,c   Gander, Bruno ^b   Lecároz, Concepción ^a   Irache, Juan M ^a   Gamazo, Carlos ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b ETH ZURICH   (Switzerland)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Biodegradable microspheres; Brucella infected monocytes; Drug delivery systems

Indexed keywords

GENTAMICIN; MICROSPHERE; PLACEBO; POLOXAMER; POLYGLACTIN;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL INFECTION; BIODEGRADABILITY; BRUCELLA ABORTUS; BRUCELLOSIS; CELL LINE; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG TARGETING; IN VITRO STUDY; INTERMETHOD COMPARISON; MACROPHAGE; MICROENCAPSULATION; MONOCYTE; MOUSE; NONHUMAN; OPSONIZATION; PARTICLE SIZE; SERUM; STATISTICAL SIGNIFICANCE; TIME;

ANIMALS; ANTI-BACTERIAL AGENTS; BRUCELLA ABORTUS; BRUCELLOSIS; CELL LINE; DRUG COMPOUNDING; GENTAMICINS; LACTIC ACID; MICE; MICROSPHERES; MONOCYTES; PARTICLE SIZE; PHAGOCYTOSIS; POLYGLYCOLIC ACID; POLYMERS; RESPIRATORY BURST;

EID: 3042641203     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh227     Document Type: Article

References (30)

1. Hall, W. H. (1990). Modern chemotherapy for brucellosis in humans. Review of Infectious Diseases 12, 1060-99.
2. Solera, J., Martinez-Alfaro, E. & Espinosa, A. (1997). Recognition and optimum treatment of brucellosis. Drugs 53, 245-56.
3. Tulkens, P. M. (1986). Experimental studies on nephrotoxicity of aminoglycosides at low doses. Mechanisms and perspectives. American Journal of Medicine 80, 105-14.
4. Gargani, G. & Pacetti, A. M. (1998). Sensitivity of 115 strains of the genus Brucella to some antibiotics (cephalosporins, ureidopenicillins and aminoglycosides). Chemioterapia 5, 7-13.
5. Vitas, A. I., Díaz, R. & Gamazo, C. (1996). Effect of composition and method of preparation of liposomes on their stability and interaction with murine monocytes infected with Brucella abortus. Antimicrobial Agents and Chemotherapy 40, 146-51.
6. Codde, J. P., Lumsden, A. J., Napoli, S. et al. (1993). A comparative study of the anticancer efficacy of doxorubicin carrying microspheres and liposomes using a rat liver tumour model. Anticancer Research 13, 539-43.
7. Thomasin, C., Corradin, G., Men, Y. et al. (1996). Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/poly(lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response. Journal of Controlled Release 41, 131-45.
8. Barrow, E. L. W., Winchester, G. A., Staas, J. K. et al. (1998). Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrobial Agents and Chemotherapy 42, 2682-9.
9. Dutt, M. & Khuller, G. K. (2001). Therapeutic efficacy of poly(DL-lactide-co-glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice. Antimicrobial Agents and Chemotherapy 45, 363-6.
10. Puisieux, F., Barrat, G., Couarraze, G. et al. (1994). Polymeric micro- and nanoparticles as drug carriers. In Polymeric Biomaterials (Dumitriu, S., Ed.), pp. 749-94. Marcel Dekker, New York, Basle, Hong Kong.
11. Quenelle, D. C., Winchester, G. A., Staas, J. K. et al. (2001). Treatment of tuberculosis using a combination of sustained-release rifampicin-loaded microspheres and oral dosing with isoniazid. Antimicrobial Agents and Chemotherapy 45, 1637-44.
12. Prior, S., Gander, B., Blarer, N. et al. (2002). In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. European Journal of Pharmaceutical Sciences 15, 197-207.
13. Murillo, M., Gamazo, C., Goñi, M. M. et al. (2002). Development of microparticles prepared by spray-drying as a vaccine delivery system against brucellosis. International Journal of Pharmaceutics 242, 341-4.
14. Prior, S., Gamazo, C., Irache, J. M. et al. (2000). Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections. International Journal of Pharmaceutics 196, 115-25.
15. Rastogi, N., Potar, M. C. & David, H. L. (1987). Intracellular growth of pathogenic mycobacteria in the continuous murine macrophage cell line J774: ultrastructure and drug-susceptibility studies. Current Microbiology 16, 79-92.
16. Kreutzer, D. L., Dreyfus, L. A. & Robertson, D. C. (1979). Interaction of polymorphonuclear leukocytes with smooth and rough strains of Brucella abortus. Infection and Immunity 23, 737-42.
17. Drevets, D. A., Canono, B. P., Leenen, P. J. M. et al. (1994). Gentamicin kills intracellular Listeria monocytogenes. Infection and Immunity 62, 2222-8.
18. Rudt, S. & Müller, R. H. (1993). In vitro phagocytosis assay of nano- and microparticles chemiluminescence. II. Effect of surface modification by coating of particles with poloxamer on the phagocytic uptake. Journal of Controlled Release 25, 51-9.
19. Müller, R. H. (1991). Modification of drug carriers. In Colloidal Carriers for Controlled Drug Delivery and Targeting (Mü ller, R. H., Ed.), pp. 19-41. Wissenschaftliche Verlagsgesellschaft, Stuttgart, CRC Press, Boca Raton, Ann Arbor, Boston, USA.
20. Illum, L., Jacobsen, L. O., Müller, R. H. et al. (1987). Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages. Biomaterials 8, 113-7.
21. Batrakova, E., Lee, S., Li, S. et al. (1999). Fundamental relationships between the composition of pluronic block copolymers and their hypersensitisation effect in MDR cancer cells. Pharmaceutical Research 16, 1373-9.
22. Miller, D. W., Batrakova, E. V. & Kabanov, A. V. (1999). Inhibition of multidrug resistance associated protein (MRP) functional activity with pluronic block polymers. Pharmaceutical Research 16, 396-401.
23. Espuelas, S., Legrand, P., Loiseau, P. M. et al. (2000). In vitro reversion of amphotericin B resistance in Leishmania donovani by poloxamer 188. Antimicrobial Agents and Chemotherapy 44, 2190-2.
24. Hunter, R. L., Jagannath, C., Tinkley, A. et al. (1995). Enhancement of antibiotic susceptibility and suppression of Mycobacterium avium complex growth by poloxamer 331. Antimicrobial Agents and Chemotherapy 39, 435-9.
25. Jagannath, C., Sepulveda, E., Actor, J. K. et al. (2000). Effect of poloxamer CRL-1072 on drug uptake and nitric-oxide-mediated killing of Mycobacterium avium by macrophages. Immunopharmacology 48, 185-97.
26. Newman, M. J., Actor, J. K., Balussubramian, M. et al. (1998). Use of ionic block copolymers in vaccines and therapeutics. Critical Reviews in Therapeutic Drug Carrier Systems 15, 89-142.
27. Frenchick, P. J., Markham, R. J. F. & Cochrane, A. H. (1985). Inhibition of phagosome-lysosome fusion in macrophages by soluble extracts of virulent Brucella abortus. American Journal of Veterinary Research 46, 332-5.
28. Pizarro-Cerdá, J., Moreno, E., Sanguedolce, V. et al. (1998). Virulent Brucella abortus prevents lysosome fusion and is distributed within autophagosome-like compartments. Infection and Immunity 66, 2387-92.
29. Detilleux, P. G., Deyoe, B. L. & Cheville, N. F. (1990). Entry and intracellular localization of Brucella spp. in Vero cells: fluorescence and electron microscopy. Veterinary Pathology 27, 317-28.
30. Pizarro-Cerdá, J., Meresse, S., Parton, R. G. et al. (1998). Brucella abortus transits through the autophagic pathway and replicates in the endoplasmic reticulum of nonprofessional phagocytes. Infection and Immunity 66, 5711-24.